Herein the inventors demonstrate that mineralization is a natural ability of cells cultured with at least two elements: calcium and acyclic alkane phosphoester salt or inorganic phosphate salt. The present invention provides methods for producing hydroxyapatite (HAP) in cell culture by supplying cells with these elements. The natural HAP crystals produced by these methods may be utilized in biomedical applications such as bone grafting. Also provided are methods of measuring organic phosphates in a sample from a subject and methods of measuring the glycerophosphates in a sample from a subject.

The present disclosure relates to a bio-material composition comprising a dry potassium phosphate based mixture omprising: MgO, monobasic potassium phosphate, monobasic sodium phosphate, proteoglycans, calcium sodium phosphosilicate, and an antibiotic, wherein a weight percent ratio of monobasic potassium phosphate to MgO is between about 3:1 and 1:1, wherein the dry otassium phosphate based mixture is configured to be mixed with the aqueous solution to thereby form a reabsorbable bio-material slurry, wherein the proteoglycans are between about 1-10 weight percent of the dry composition, and wherein the proteoglycans act as active regulators of collagen fibrillogenesis to thereby structure tissue of a patient by organizing a bone extracellular matrix.

The present disclosure relates to a bio-material composition comprising a dry potassium phosphate based mixture omprising: MgO, monobasic potassium phosphate, monobasic sodium phosphate, proteoglycans, calcium sodium phosphosilicate, and an antibiotic, wherein a weight percent ratio of monobasic potassium phosphate to MgO is between about 3:1 and 1:1, wherein the dry otassium phosphate based mixture is configured to be mixed with the aqueous solution to thereby form a reabsorbable bio-material slurry, wherein the proteoglycans are between about 1-10 weight percent of the dry composition, and wherein the proteoglycans act as active regulators of collagen fibrillogenesis to thereby structure tissue of a patient by organizing a bone extracellular matrix.

The present disclosure features adhesive compositions and methods of use thereof related to the medical, veterinary, and dental fields.

The present disclosure features adhesive compositions and methods of use thereof related to the medical, veterinary, and dental fields.

The present disclosure provides a bone-implantable device and methods of use. The bone-implantable device comprises a body having an exterior surface, wherein a portion of the exterior surface includes a cured osteostimulative material comprising MgO.

The present disclosure provides a bone-implantable device and methods of use. The bone-implantable device comprises a body having an exterior surface, wherein a portion of the exterior surface includes a cured osteostimulative material comprising MgO.

An implant for treating a bone defect wherein the implant comprises osteoconductive supporting bodies and an insertion aid. The insertion aid is designed for insertion of the osteoconductive supporting bodies into a bone defect and for holding together the osteoconductive supporting bodies. Also disclosed is a kit comprised of an implant for treating a bone defect.

An implant for treating a bone defect wherein the implant comprises osteoconductive supporting bodies and an insertion aid. The insertion aid is designed for insertion of the osteoconductive supporting bodies into a bone defect and for holding together the osteoconductive supporting bodies. Also disclosed is a kit comprised of an implant for treating a bone defect.

An inducer is directed to the induction of in situ regeneration in regenerative medicine. The inducer including an extracellular matrix and/or a bone morphogenetic protein, can induce the regeneration of bone and soft tissues surrounding the bone such as muscle, blood vessel and skin at the residual tissues where trauma occurs. The amount of regenerated tissue is associated with the dose of the implanted inducer.